Levetiracetam vs Phenobarbital for Neonatal Seizures

Phase 4, randomised, open-label trial of levetiracetam in neonatal seizures (2 arms), sponsored by Cairo University. Primary endpoints: Efficacy of levetiracetam in control of neonatal seizures as a first line versus phenobarbital through assessment of seizure burden at 72 hours and Efficacy of levetiracetam in rapid control of neonatal seizures compared to phenobarbital at 72 hours. Status: unknown.